Ebb & Flow

Investors voted with their feet after learning that they will have to wait even longer for regulatory clarity over competing compounds for Fabry disease from Genzyme (GENZ) and Transkaryotic (TKTX).

On Friday, the FDA postponed this week's meetings of the Endocrinologic and Metabolic Drugs Advisory Committee to review GENZ's Fabrazyme agalsidase beta and Replagal agalsidase alfa from TKTX. Both therapeutics are marketed in Europe, but the BLAs have been at the FDA for more than two years...